Adjustable technology for controlled & sustained release with Long-Acting Injectable Technology · Low polymer COGS · Precise formulations · Value innovation.
Location: France, Occitania, Montpellier
Total raised: $19M
Founded date: 2002
Investors 2
| Date | Name | Website |
| - | Credit Mut... | creditmutu... |
| 10.07.2026 | Kurma Part... | kurmapartn... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 04.12.2019 | Grant | $19M | - |
Mentions in press and media 3
| Date | Title | Description |
| 25.10.2021 | MedinCell : Announces Participation in the Jefferies London Healthcare Conference 2021 | Regulatory News: MedinCell (Paris:MEDCL) will be attending the 12th Jefferies London Healthcare Conference on Tuesday, November 16 and Wednesday, November 17 at the Waldorf Hilton in London. The conference will be, notably, the opportunity ... |
| 04.08.2021 | Participation terms in the MedinCell Combined General Meeting | Regulatory News: MedinCell (Paris:MEDCL) will hold a video conference on Monday, August 30, 2021 at 6:30 pm to present the resolutions of the Annual General Meeting and answer questions from shareholders. Connection link: https://invest.med... |
| - | Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis | MONTPELLIER, France--(BUSINESS WIRE)--Mar 5, 2021-- MedinCell (Paris:MEDCL): No safety concern is anticipated that would prevent health authorities from assessing the use of Ivermectin against Covid-19 as a new indication The expert review ... |